Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY Annals of Clinical and Translational Neurology Pub Date : 2025-02-11 DOI:10.1002/acn3.52301

Young Nam Kwon, Nanthaya Tisavipat, Yong Guo, Stephanie B. Syc-Mazurek, Ji Yeon Han, Jun-Soon Kim, Kyomin Choi, Seong-il Oh, Seok-Jin Choi, Eunhee Sohn, Jeeyoung Oh, Seung Woo Kim, Ha Young Shin, Byung Chan Lim, Byoung Joon Kim, Kyung Seok Park, Jung-Joon Sung, Se Hoon Kim, Sung-Hye Park, Anastasia Zekeridou, Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung-Min Kim

{"title":"Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD","authors":"Young Nam Kwon, Nanthaya Tisavipat, Yong Guo, Stephanie B. Syc-Mazurek, Ji Yeon Han, Jun-Soon Kim, Kyomin Choi, Seong-il Oh, Seok-Jin Choi, Eunhee Sohn, Jeeyoung Oh, Seung Woo Kim, Ha Young Shin, Byung Chan Lim, Byoung Joon Kim, Kyung Seok Park, Jung-Joon Sung, Se Hoon Kim, Sung-Hye Park, Anastasia Zekeridou, Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung-Min Kim","doi":"10.1002/acn3.52301","DOIUrl":null,"url":null,"abstract":"<p>Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; <i>P</i> < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.</p>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":"12 4","pages":"861-870"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52301","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.52301","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MOGAD并发肿瘤和副肿瘤相关性的评估。

髓鞘少突胶质细胞糖蛋白（MOG）抗体相关疾病（MOGAD）与肿瘤共同发生的病例已有报道。在韩国和美国进行的这项国际回顾性队列研究中，445例MOGAD患者中有16例（3.6%）在MOGAD发病2年内并发肿瘤，肿瘤标准化发病率为3.10(95%可信区间[CI]， 1.77-4.81；P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)

CiteScore

9.10

自引率

1.90%

发文量

218

审稿时长

8 weeks

期刊介绍： Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.